Positive effects of Vildagliptin and its combinations
with Metformin in therapy of patients with type 2 diabetes
and comorbid pathology
Sayenko Ya. A.
In recent years, in the pathogenesis of such diseases as diabetes, obesity, hypertension, such an important link of pathogenesis as inflammation is also considered. Inflammation of any genesis is included in its own in the development of microcirculation disorders, which in turn are associated with endothelial dysfunction. Therefore, the latter is considered a common link in the pathogenesis of type 2 diabetes, obesity and their complications. Modern treatment of type 2 diabetes involves the use of Metformin and highly selective dipeptidyl peptidase 4 (DPP-4) inhibitors, in particular Vildagliptin. There are also combinations of these two medications, as, for example, in the composition of the medication “Aiglimet” produced by Ukrainian company Farmak. This review summarizes the results of the latest global research effects of combination of the medications Metformin and Vildagliptin on the course of type 2 diabetes, obesity, cardiovascular diseases, cognitive dysfunctions, etc. There are also data on molecular mechanisms of the endothelioprotective functions of these medications.
Keywords: type 2 diabetes, endothelial dysfunction, treatment of type 2 diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors.